Johannes Streffer

CSF tau as a biomarker of therapeutic effect

Potential benefits of an anti-Aβ vaccine over monoclonal antibodies

Optimized anti-Aβ vaccination enters clinical trials in Alzheimer’s disease

Is amyloid lowering still a valid approach in Alzheimer’s disease?